American journal of perinatology · 2026
Smartphone-Based Screening for Neonatal Hyperbilirubinemia in a U.S. Tertiary Center.
Клиническое исследованиеСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Schied Jeanmarie, Onishchenko Elizabeth, Traversari Caden, Louzon Matthew, Hill Deborah
Аннотация
OBJECTIVE: Noninvasive screening for neonatal hyperbilirubinemia typically requires dedicated transcutaneous bilirubin devices, which may not be universally available. Smartphone-based screening tools offer a potential alternative but remain incompletely validated in U.S. clinical settings. We evaluated the accuracy of the Picterus Jaundice Pro smartphone application (app) compared with total serum bilirubin (TSB) in a diverse U.S. newborn population.
STUDY DESIGN: A prospective, cross-sectional study of 74 newborns (gestational age ≥35 weeks, birth weight ≥1,800 g, age >21 hours to 14 days) admitted to the nursery or neonatal intensive care unit (NICU) was performed. Within 60 minutes of clinically indicated TSB collection, trained staff placed a calibration card on the infant's chest and used the smartphone Picterus Jaundice Pro app to obtain two scans (six images per scan). Images were analyzed by an algorithm to estimate bilirubin levels. Staff were blinded to application results.
RESULTS: App estimates correlated with TSB (r = 0.72, p < 0.001). Using 2022 American Academy of Pediatrics (AAP) phototherapy criteria, the app correctly identified all infants requiring phototherapy (sensitivity 100%; 95% confidence interval [CI] 54.1-100%) with 78% specificity (95% CI 67.8-87.0%) and 100% negative predictive value (95% CI 94.2-100%). Bland-Altman analysis yielded a mean bias of -2.1 mg/dL (95% limits of agreement: -7.8 to +3.6 mg/dL). These results provide an indirect comparison with performance for currently reported transcutaneous devices.
CONCLUSION: The Picterus Jaundice Pro app correlated with TSB and identified all infants requiring phototherapy based on current AAP thresholds, suggesting potential utility as a noninvasive smartphone-based screening tool for neonatal hyperbilirubinemia.
CONCLUSION: KEY POINTS.
CONCLUSION: · Current neonatal hyperbilirubinemia tools can be costly.. · Access may be limited in low-resource settings.. · Mobile health may expand hyperbilirubinemia screening.. · Picterus Jaundice Pro showed safe screening performance.. · The app may also offer a low-cost alternative..
STUDY DESIGN: A prospective, cross-sectional study of 74 newborns (gestational age ≥35 weeks, birth weight ≥1,800 g, age >21 hours to 14 days) admitted to the nursery or neonatal intensive care unit (NICU) was performed. Within 60 minutes of clinically indicated TSB collection, trained staff placed a calibration card on the infant's chest and used the smartphone Picterus Jaundice Pro app to obtain two scans (six images per scan). Images were analyzed by an algorithm to estimate bilirubin levels. Staff were blinded to application results.
RESULTS: App estimates correlated with TSB (r = 0.72, p < 0.001). Using 2022 American Academy of Pediatrics (AAP) phototherapy criteria, the app correctly identified all infants requiring phototherapy (sensitivity 100%; 95% confidence interval [CI] 54.1-100%) with 78% specificity (95% CI 67.8-87.0%) and 100% negative predictive value (95% CI 94.2-100%). Bland-Altman analysis yielded a mean bias of -2.1 mg/dL (95% limits of agreement: -7.8 to +3.6 mg/dL). These results provide an indirect comparison with performance for currently reported transcutaneous devices.
CONCLUSION: The Picterus Jaundice Pro app correlated with TSB and identified all infants requiring phototherapy based on current AAP thresholds, suggesting potential utility as a noninvasive smartphone-based screening tool for neonatal hyperbilirubinemia.
CONCLUSION: KEY POINTS.
CONCLUSION: · Current neonatal hyperbilirubinemia tools can be costly.. · Access may be limited in low-resource settings.. · Mobile health may expand hyperbilirubinemia screening.. · Picterus Jaundice Pro showed safe screening performance.. · The app may also offer a low-cost alternative..